POS1328 DO IL-1 ANTAGONISTS DEFINITELY PROTECT FROM THE DEVELOPMENT OF NEW DAMAGE: A SINGLE-CENTER STUDY

Background Ongoing inflammatory episodes of familial Mediterranean fever (FMF) disease can cause damage in nearly all organ systems. Colchicine and interleukin1β blocking agents are successfully used to control the activity [1]. Although effect IL-1 blockers known for controlling amyloidosis [2], it is unclear whether they prevent Objectives In our study, we assessed patients with FMF treated colchicine antagonists (IL-1A). It was evaluated new occurred after antagonist treatment. Methods A total 111 fulfilling Tel-Hashomer criteria IL-1A due resistance were included study. All also a maximum-tolerable dose. Patients grouped according their recent status (no damage, pre-existing developed under treatment). The degree determined using Autoinflammatory Disease Damage Index (ADDI) modified form ADDI (mADDI) [3, 4]. Results 44 (42,3%) had index; three experienced treatment while four showed progression mADDI score. positive score, most common (n=28, 63%), second frequent musculoskeletal findings (N=14, 31%), third infertility (N=2, 0,04%). domains FMF-related (n=4), renal (n=2) reproductive system Conclusion Our study first evaluate treated- antagonists. that effective colchicine-resistant patients, physicians should be aware still develop References [1]Chae JJ, Aksentijevich I, Kastner DL. Advances understanding possibilities targeted therapy. Br J Haematol 2009; 146:467–78. [2]Ozcakar ZB, Ozdel S, Yilmaz Kurt-Sukur ED, Ekim M et al. Anti-IL-1 related amyloidosis. Clinical Rheumatology 2016; 35 (2): 441- 446. doi: 10.1007/s10067-014-2772-2 [3]Ter Haar NM, Annink KV, Al-Mayouf SM al.: Development autoinflammatory index (ADDI). Ann Rheum Dis 2017; 76: 821-30 [4]Babaoglu H, Armagan B, Bodakci E, Satis Atas N, Sari A, Yasar Bilge NS, Bilici Salman R, Yardimci GK, Avanoglu Guler Karadeniz Kilic L, Ozturk MA, Goker Haznedaroglu Kalyoncu U, Kasifoglu T, Tufan A. Factors associated fever. Clin Exp Rheumatol. 2020 Sep-Oct;38 Suppl 127(5):42-48. Table 1. Comparison clinical laboratory parameters between groups No New Any P value Age (years) 48,4 56,4 67,5 0,002 Sex (K/E) 34/33 2/5 25/19 NS Follow-up time 40 43 56 0,33 Dominant attack type Peritonitis(63,7%) NA Arthritis(34,1%) Persistent inflammation 33,6 42,3 44,3 0,05 AIDAI score 39 48 Mutations M694V/M694V 26 2 14 M694V/any 4 38 M694V/M680I 3 1 M680I/any 11 9 •SAIDAI: Auto-Inflammatory Diseases Activity Acknowledgements participants confirmed both participation publication. Local Ethical Committee approved Disclosure Interests None declared